Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized...
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
About this item
Full title
Author / Creator
Publisher
United States: National Academy of Sciences
Journal title
Language
English
Formats
Publication information
Publisher
United States: National Academy of Sciences
Subjects
More information
Scope and Contents
Contents
The only causative treatment for IgE-mediated allergies is allergen-specific immunotherapy. However, fewer than 5% of allergy patients receive immunotherapy because of its long duration and risk of allergic side effects. We aimed at enhancing s.c. immunotherapy by direct administration of allergen into s.c. lymph nodes. The objective was to evaluat...
Alternative Titles
Full title
Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_fao_agris_US201301562506
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_fao_agris_US201301562506
Other Identifiers
ISSN
0027-8424
E-ISSN
1091-6490
DOI
10.1073/pnas.0803725105
